A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats

British Journal of Ophthalmology

Volumn 92, Issue 4, 2008, Pages 545-547

  Bhatwadekar, A ^a   Glenn, J V ^a   Figarola, J L ^b   Scott, S ^b   Gardiner, T A ^a   Rahbar, S ^b   Stitt, A W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DRINKING WATER; HEMATOXYLIN; LR 90; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; ENUCLEATION; MICROSCOPY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; RAT; STAINING; STREPTOZOCIN DIABETES;

ANIMALS; BODY WEIGHT; BUTYRATES; CHOLESTEROL; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 41849131467     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.127910     Document Type: Article

References (19)

1. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989;38:1203-6.
2. Bhatwadekar A, Stitt AW. AGE and RAGE inibitors in the treatment of diabetic retinopathy. Expert Rev Ophthalmol 2007;2:105-20.
3. Fosmark DS, Torjesen PA, Kilhovd BK, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006;55:232-6.
4. Nakamura N, Hasegawa G, Obayashi H, et al. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract 2003;61:93-101.
5. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003;17:16-21.
6. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-11.
7. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-80.
8. Canning P, Glenn JV, Hsu DK, et al. Inhibition of advanced glycation and absence of galectin-3 prevents blood retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007;2007:51837.
9. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2826-32.
10. Dobler D, Ahmed N, Song L, et al. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006;55:1961-9.
11. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001;50:1636-42.
12. Rahbar S, Kumar Yernini K, Scott S, et al. Novel inhibitors of advanced glycation endproducts. Biochem Biophys Res Commun 1999;262:651-6.
13. Figarola JL, Scott S, Loera S, et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003;46:1140-52.
14. Figarola JL, Shanmugam N, Natarajan R, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007;56:647-55.
15. Rahbar S, Yerneni KK, Scott S, et al. Novel inhibitors of advanced glycation endproducts (part II). Mol Cell Biol Res Commun 2000;3:360-6.
16. Ahmed MU, Brinkmann Frye E, Degenhardt TP, et al. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324:565-70.
17. Price DL, Rhett PM, Thorpe SR, et al. Chelating activity of advanced glycation endproduct inhibitors. J Biol Chem 2001;276:48967-72.
18. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:2916-24.
19. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 2007;48:147-57.